Optimizing Antiplatelet Therapy in Cardiogenic Shock-The Use of Cangrelor in ACS and Cardiogenic Shock: Lessons Learned from Trial and Registry Data

The Use of Cangrelor in ACS and Cardiogenic Shock: Lessons Learned from Trial and Registry Data

Video Transcription

Video Summary

In this video, an interventional cardiologist discusses the use of cangrelor in patients with acute coronary syndrome (ACS) and cardiogenic shock. He talks about the indication and evidence for cangrelor in PCI, as well as its use in ACS patients. He also discusses the use of cangrelor in patients with cardiogenic shock, citing observational data. The cardiologist highlights the importance of using cangrelor correctly, particularly when transitioning to other antiplatelet therapies. He also mentions ongoing trials that are investigating the use of cangrelor in cardiogenic shock and out-of-hospital cardiac arrest. The video concludes with the need for further research on outcomes and bleeding risk in patients with cardiogenic shock.

Asset Subtitle

Jennifer A. Rymer, MD, MBA, MHS

Keywords

cangrelor

acute coronary syndrome

cardiogenic shock

PCI

observational data